0
0
0
Ending the Prescription Drug Kickback Act of 2023
12/15/2023, 4:07 PM
Summary of Bill S 1217
Bill 118 s 1217, also known as the Ending the Prescription Drug Kickback Act of 2023, is a piece of legislation introduced in the US Congress with the aim of addressing the issue of kickbacks in the prescription drug industry.
The bill seeks to prohibit pharmaceutical companies from providing kickbacks or other incentives to healthcare providers in exchange for prescribing their drugs. This practice has been criticized for driving up healthcare costs and potentially compromising patient care by influencing doctors' prescribing decisions.
If passed, the Ending the Prescription Drug Kickback Act of 2023 would impose penalties on pharmaceutical companies found to be engaging in kickback schemes, including fines and potential criminal charges. The bill also includes provisions for increased transparency and reporting requirements to ensure compliance with the new regulations. Overall, the goal of this legislation is to promote fair competition in the prescription drug market and protect patients from potential conflicts of interest that may arise from kickback arrangements between pharmaceutical companies and healthcare providers.
The bill seeks to prohibit pharmaceutical companies from providing kickbacks or other incentives to healthcare providers in exchange for prescribing their drugs. This practice has been criticized for driving up healthcare costs and potentially compromising patient care by influencing doctors' prescribing decisions.
If passed, the Ending the Prescription Drug Kickback Act of 2023 would impose penalties on pharmaceutical companies found to be engaging in kickback schemes, including fines and potential criminal charges. The bill also includes provisions for increased transparency and reporting requirements to ensure compliance with the new regulations. Overall, the goal of this legislation is to promote fair competition in the prescription drug market and protect patients from potential conflicts of interest that may arise from kickback arrangements between pharmaceutical companies and healthcare providers.
Congressional Summary of S 1217
Ending the Prescription Drug Kickback Act of 2023
This bill generally prohibits prescription drug manufacturers from providing rebates to pharmacy benefit managers (PBMs) or private health insurance plans.
Specifically, the bill eliminates the safe harbor for rebates, or other payments, provided to PBMs that are intended to influence the applicable cost-sharing tier of the drug (e.g., placing the drug in a more favorable formulary tier).
The bill further prohibits health insurance plans from receiving such rebates with respect to a prescription drug covered by the plan. Plans also must ensure PBMs do not receive any such rebates.
Read the Full Bill
Current Status of Bill S 1217
Bill S 1217 is currently in the status of Bill Introduced since April 19, 2023. Bill S 1217 was introduced during Congress 118 and was introduced to the Senate on April 19, 2023. Bill S 1217's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of April 19, 2023
Bipartisan Support of Bill S 1217
Total Number of Sponsors
1Democrat Sponsors
0Republican Sponsors
1Unaffiliated Sponsors
0Total Number of Cosponsors
0Democrat Cosponsors
0Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill S 1217
Primary Policy Focus
HealthAlternate Title(s) of Bill S 1217
Ending the Prescription Drug Kickback Act of 2023
Ending the Prescription Drug Kickback Act of 2023
A bill to prohibit the distribution and receipt of rebates for prescription drugs.
Comments
Sponsors and Cosponsors of S 1217
Latest Bills
Providing for consideration of the bill (H.R. 8035) to amend the FISA Amendments Act of 2008 to extend the authorities of title VII of the Foreign Intelligence Surveillance Act of 1978 through October 20, 2027, and for other purposes.
Bill HRES 1175April 17, 2026
Social Determinants for Moms Act
Bill S 4149April 17, 2026
FARM Stability Act
Bill S 4249April 17, 2026
Investing in All of America Act of 2025
Bill HR 2066April 17, 2026
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Bureau of Land Management relating to Public Land Order No. 7917 for Withdrawal of Federal Lands; Cook, Lake, and Saint Louis Counties, MN.
Bill HJRES 140April 17, 2026
A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress.
Bill SJRES 123April 17, 2026
A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress.
Bill SJRES 116April 17, 2026
A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress.
Bill SJRES 181April 17, 2026
A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress.
Bill SJRES 183April 17, 2026
A joint resolution to direct the removal of United States Armed Forces from hostilities within or against the Islamic Republic of Iran that have not been authorized by Congress.
Bill SJRES 171April 17, 2026